Released on: 11 January 2021
NCT responds to today’s strategy announced by the Medicines and Healthcare Products Regulatory Agency (MHRA) to improve information for pregnant and breastfeeding women
“NCT has welcomed the opportunity to be a leading voice for parents in this important consortium at the MHRA, following its establishment in 2018. Even before the COVID-19 pandemic, it was clear that fresh energy and engagement were needed to improve information on medicines for those who are expecting babies or breastfeeding them.
“It is essential that women and their families have access to clear, evidence-based information and are supported to make informed decisions on medicines during pregnancy and breastfeeding. It is also vital that robust research is conducted to fill gaps in knowledge, to enable safety assurance and make sure women aren’t unnecessarily limited in their healthcare options.
“We look forward to future work with the consortium, to enhance knowledge and reduce anxieties for women who need safe treatment for their healthcare and the wellbeing of their babies”.
